key: cord-0876000-2m9nchys
authors: Taghavi-farahabadi, Mahsa; Mahmoudi, Mohammad; Soudi, Sara; Mahmoud Hashemi, Seyed
title: Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes
date: 2020-05-22
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.109865
sha: 203465d83ebc574c7b4e683273a971756743548b
doc_id: 876000
cord_uid: 2m9nchys

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronaviridae that causes respiratory disorders. After infection, large amounts of inflammatory cytokines are secreted, known as the cytokine storm. These cytokines can cause pulmonary damage induced by inflammation resulting in acute respiratory distress syndrome (ARDS), and even death. One of the therapeutic approaches for treatment of ARDS is a mesenchymal stem cell (MSC). MSCs suppress inflammation and reduce lung injury through their immunomodulatory properties. MSCs also have the potential to prevent apoptosis of the lung cells and regenerate them. But our suggestion is using MSCs-derived exosomes. Because these exosomes apply the same immunomodulatory and tissue repair effects of MSCs and they don’t have problems associated to cell maintenance and injections. For investigation the hypothesis, MSCs should be isolated from tissues and characterized. Then, the exosomes should be isolated from the supernatants and characterized. These exosomes should be injected into a transgenic animal for COVID-19. In the final section, lung function assessment, histological examination, micro-CT, differential leukocyte, viral load analysis, cytokine assay, and CRP level analysis can be investigated. COVID-19 treatment is currently focused on supportive therapies and no vaccine has not been developed for it, so, numerous research studies are needed to find potential. Since the pathogenesis of this disease was identified in previous studies and can cause lung injury with ARDS, so, investigation of the therapeutic approaches that can suppress inflammation, cytokine storm and ARDS can be helpful in finding a novel therapeutic approach for this disease.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronaviridae that causes respiratory disorders. After infection, large amounts of inflammatory cytokines are secreted, known as the cytokine storm. These cytokines can cause pulmonary damage induced by inflammation resulting in acute respiratory distress syndrome (ARDS), and even death.

One of the therapeutic approaches for treatment of ARDS is a mesenchymal stem cell (MSC). MSCs suppress inflammation and reduce lung injury through their immunomodulatory properties. MSCs also have the potential to prevent apoptosis of the lung cells and regenerate them. But our suggestion is using MSCs-derived exosomes. Because these exosomes apply the same immunomodulatory and tissue repair effects of MSCs and they don't have problems associated to cell maintenance and injections.

For investigation the hypothesis, MSCs should be isolated from tissues and characterized.

Then, the exosomes should be isolated from the supernatants and characterized. These exosomes should be injected into a transgenic animal for COVID-19. In the final section, lung function assessment, histological examination, micro-CT, differential leukocyte, viral load analysis, cytokine assay, and CRP level analysis can be investigated.

COVID-19 treatment is currently focused on supportive therapies and no vaccine has not been developed for it, so, numerous research studies are needed to find potential. Since the pathogenesis of this disease was identified in previous studies and can cause lung injury with ARDS, so, investigation of the therapeutic approaches that can suppress inflammation, cytokine storm and ARDS can be helpful in finding a novel therapeutic approach for this disease.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the family coronaviridae that, like two other members of the family, coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), causes respiratory disorders [1, 2] . The virus was first detected in Wuhan, China, on December 2019, and the disease caused by the virus, Coronavirus disease (COVID- 19) , was characterized as a pandemic on 11 March 2020 by the World Health Organization (WHO) [3, 4] .

that can encode a number of structural proteins such as M (matrix), E (envelope), N (nucleocapsid) and S (spike) protein as well as a number of non-structural proteins. Among these structural proteins, the S protein binds to the angiotensin-converting enzymes 2 (ACE2) present on the surface of human cells, especially the alveolar type II cells that highly express this receptor, and then the virus enters the host lung cells [5, 6] . Effective immune responses against viral infections depend on IFN-I production from innate immune cells and subsequently cell mediated immunity through T helper 1 and cytotoxic T cells [5] . So, as the virus enters the cell, its genome is recognized by various pattern recognition receptors (PRRs) such as toll-like receptor-3 (TLR-3), TLR7-9, retinoic acid-inducible gene-I (RIG-I), Melanomadifferentiation-associated gene 5 (MDA5), and Cyclic GMP-AMP synthase (cGAS), then signaling pathways are initiated. Following these incidences, large amounts of type I interferons and inflammatory cytokines are secreted [7] [8] [9] [10] . Following these inflammatory conditions in the lungs, which also increase with the proliferation of the virus, a sharp increase in inflammatory cytokines such as IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1A, and

TNFα have been reported in patients with COVID, known as the cytokine storm [11] . This cytokine storm is similar to that seen in SARS and MERS and is caused by the lack of proper regulation of inflammatory immune responses [12, 13] .

Clinical Evidences demonstrated that this cytokine storm is the main cause of acute respiratory distress syndrome (ARDS) in COVID-19 [5, [12] [13] [14] . Pathogenic T cells produce inflammatory cytokines after activation and subsequently inflammatory monocytes and other leukocytes migrate to the lung [15] . Increased neutrophil counts have been reported as a symptom in a number of patients [2] . These activated immune cells may cause pulmonary damage induced by inflammation resulting in complications such as pneumonia, loss of lung function, ARDS, and even death (Fig. 1A ) [5, [12] [13] [14] . Since ARDS is recognized as one of the leading causes of mortality in patients and appears to be caused by cytokine storm, so, suppression of this inflammation may cause decrease inflammatory cytokine production and consequently reduce inflammation and lung injury. As has been shown, the use of Anti-IL6 in patients with COVID-19-induced pneumonia can be useful and has been approved in China [16] . Currently, there is no approved treatment for SARS-CoV-2, and usually supportive treatments such as the use of ventilators and muscle relaxants were used for these patients [6, 16, 17] . Numerous therapeutic interventions have been performed to treat ARDS, but since the mechanisms of damage in ARDS are complex and diverse, it seems that therapeutic strategies that target a single pathway or mediator cannot be useful in achieving therapeutic outcome [17] . Therefore, interventions that target several aspects of immunopathogenesis and associated injuries, can be helpful to find the appropriate treatment strategy. [19] [20] [21] [22] [23] [24] . MSCs are the multipotent cells that can be obtained from different tissues such as, adipose tissue and bone marrow. These cells have the self-renewing capacity and can be differentiated into chondrogenic, osteogenic and adipogenic lineages [25] . Several features of these cells have made them an appealing candidate for the treatment of many diseases, including ARDS.  Immunomodulatory properties: MSCs able to alter the function of the immune cells and modulate the immune response [17] . For example, In LPS-induced ARDS animal models, it has been shown that, MSCs suppress inflammation and reduce inflammationinduced lung injury through their immunomodulatory properties. These cells affect the macrophages by releasing prostaglandin E2 (PG-E2), and reduce the production of inflammatory cytokines and increase IL-10 production. IL-10 reduced neutrophils recruitment to the lungs and attenuated inflammatory cytokine production [20, 22, 24] .

MSCs can also increase regulatory T cells and alter the phenotype of macrophages to M2 macrophages [17] .

 Tissue repair characteristic: MSCs also have the potential to repair tissue and can prevent apoptosis of the lung cells and regenerate them, especially type II alveolar cells by producing growth factors such as keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF). This characteristic is important because people with ARDS develop pulmonary fibrosis even after surviving the acute phase of the disease [19, 21, 26] . MSCs can restore epithelial protein permeability by secretion of angiopoietin-1. These cells can increase phagocytosis capacity of the macrophages by transferring the microvesicles [17] .

 Some studies shown that MSCs could imply antiviral activity. It was shown that gammaherpesvirus infected MSCs could limit the replication of the virus after sensing its DNA by cGAS and initiation of the STING-TBK1 signaling pathway. This pathway that is resulted in IFN-γ production along with IFN-γ independent manner could be responsible for the anti-viral response of the MSCs [27] . In addition, some studies shown that IDO, which expressed by MSCs, could responsible for anti-viral activity of the MSCs [28] [29] [30] . IDO-positive MSCs triggered by inflammatory cytokines demonstrated antimicrobial effector function against pathogens such as viruses [28] . In a study performed in 2011, it was shown that IFN-γ stimulated the expression of the IDO in MSCs and the replication of the CMV and HSV-1 were decreased [29] .

In summary, it can be suggested that MSCs can be attractive candidates for improving COVID-19-induced ARDS and lung injury, due to their immunomodulatory, tissue repair and anti-viral characteristics (Fig 1B) .

But our suggestion is using MSCs-derived exosomes. Because it has been shown that MSC- were significantly decreased [32] . In a study performed in 2018, intravenous injection of MSCexosomes reduced the TNF-α, IL-1β, NF-κB, and matrix metallopeptidase 9 in the lung.

Another study mentioned that these exosomes could decrease endothelial cell apoptosis and IL-6 production. An increase in IL-10 production was also observed [33] . In addition to this, due to the specific structure of the exosomes, miRNAs as well as various drugs can be inserted into them. Then, after administration of these exosomes, they can be trapped in the lung tissue and reached to the target cells. These miRNAs or drugs can target the specific molecules inside the infected cells and diminish local inflammation or prevent apoptosis of the lung cells [34] .

In a Song et al. study, it was showed that pretreatment of the MSCs with IL-1β augmented their immunomodulatory effects. Because their exosomes transfer of miR-146a to the target cells [35] . Other advantages of the exosomes include ease of access, lack of problems associated to cell maintenance and injections, proper size, and finally the nature of their phospholipid membranes, which enable them to fuse with the target cell membrane and transfer the cargo into the cytoplasm. Additionally, this special structure protects the contents of the exosomes from degradation [36] .

To investigate the effects of exosomes derived from MSCs, a study can be performed according to the following steps and characteristics:

At the first section of the study, MSCs should be isolated from tissues, different sources can be chosen such as adipose tissue, bone marrow, Wharton jelly, and, etc. Second, these cells will be cultured. Then, the differentiation potential of homogenous population of spindleshaped MSCs will be determined using in vitro adipogenic and osteogenic induction. In addition, the immunophenotype of MSCs will be confirmed by measurement of CD73, CD90, CD105, CD14, CD45, CD34, and HLA-DR cell surface marker using flowcytometry. After the adaptation of the cells with serum-free medium the supernatants of them can be collected. Then, a good manufacturing practice (GMP)-grade method should be used for the isolation of the exosomes from the supernatants, as a medicinal product [37] . The next step is to characterize the exosomes. For this purpose, the size distribution of isolated exosomes will be evaluated using dynamic light scattering (DLS) and NanoSight, nanoparticle tracking analysis (NTA).

The morphology of these vesicles will be determined using scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analysis. In addition, the expression of exosome membrane specific markers including CD9, CD63 and CD81 will be assessed using western blot or flowcytometry.

The second section of the study is related to animal model preparation and exosome injection to them. It is better to choose two ARDS models that induced by different condition and compare them with each other. For example, a hACE2 transgenic animal infected with SARS-CoV-2 [38] and an LPS-induced ARDS animal [24] . Next, the isolated exosomes should be injected into these animals. Intravenous or intratracheal injection can be performed. It is suggested to use both of these routes and compare them with each other. Injection program can be designed like this: PBS, exosomes derived from other sources such as fibroblasts, MSCexosomes (dose 1), MSC-exosomes (dose 2), and other doses.

In the final section of the study, the effects of exosome injection on different groups should be measured. Lung function assessment can be investigated through arterial oxygenation and static lung compliance evaluation [22] . In addition to these, histological examination or micro-CT can be done for assessment of the lung injury. BALL is an important sample for evaluating the effects of MSC-exorcisms' on lung inflammation. After collection of the BALL sample, differential leukocyte count can be done. For the monitoring of the viral load, real time PCR is a beneficial technique. Evaluating the cytokine profile using ELISA can be useful. Another sample is blood, that differential leukocyte count, inflammatory cytokines and CRP level are the important data for evaluating MSC-exosomes effects on ARDS and cytokine storm. All of these procedure can be performed in clinical trials studies after confirmation in animal models ( Fig. 2 ).

Since COVID-19 treatment is currently focused on supportive therapies and no vaccine has not been developed for it [6] , so, numerous research studies are needed to find potential therapies to control the virus as soon as possible. Because SARS-CoV-2 has high transmission potential and spreads rapidly throughout the world and causes many deaths. Since the pathogenesis of this disease was identified partially in previous studies and there are similarities between its pathogenesis with that of other viruses in this family and some bacterial infections and can cause lung injury with ARDS [1, 5, 14] , so, investigation of the therapeutic approaches that can suppress inflammation, cytokine storm and ARDS can be helpful in finding a novel therapeutic approach for this disease. Therefore, the use of MSCs as one of the immunomodulating and tissue regenerating cells that have previously shown satisfactory effects on ARDS and cytokine storms [19, [21] [22] [23] [24] 39] could be considered. Since these cells exert their effects in a variety of ways, such as exosomes secretion, the use of their exosomes can be considered as a cell-free therapy [31] . Because these exosomes can have antiinflammatory effects on lung tissue by transferring mRNAs, miRNAs, and various proteins from its secretory cell to the target cell [40] . As previously shown, these exosomes can reduce inflammatory cytokines, increase regulatory cytokines and suppress inflammation [34] .

Monsel et al. also showed that MSC-exosomes could increase survival of alveolar type II cells by increasing intracellular ATP levels [41] . So we introduced this hypothesis in order to further study in the future and hope to see satisfactory results.

The authors have no conflict of interest.

No financial support was used for the development or writing of this manuscript. 

■The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

SARS and other coronaviruses as causes of pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Molecular immune pathogenesis and diagnosis of COVID-19

Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids

Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA

Innate immunity to virus infection

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Lung pathology of severe acute respiratory syndrome

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in Severe Pulmonary Syndrome Patients of a New Coronavirus

COVID-19: consider cytokine storm syndromes and immunosuppression

Cell-based therapy for acute respiratory distress syndrome: Biology and potential therapeutic value

Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy

The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo

Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice

The Vascular Endothelial Growth Factors-Expressing Character of Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung Injury In Vivo

Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. Coli in the rat

Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli -induced acute respiratory distress syndrome

Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung

Evaluation of the effects of mesenchymal stem cells on neutrophils isolated from severe congenital neutropenia patients

Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives

Mesenchymal stem cells detect and defend against gammaherpesvirus infection via the cGAS-STING pathway

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation

Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase

Mesenchymal Stromal cells and viral infection

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Adipose-derived mesenchymal stem cell-derived exosomes markedly protected the brain against sepsis syndrome induced injury in rat

Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options

Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem Cells Against Sepsis

Therapeutic and diagnostic applications of extracellular vesicles

Generation and testing of clinical-grade exosomes for pancreatic cancer

The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

Extracellular vesicles: biology and emerging therapeutic opportunities

Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice